$0.64
6.68% yesterday
NYSE, Jun 13, 10:10 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.64
+0.17 35.91% 1M
+0.07 12.53% 6M
+0.04 5.97% YTD
-0.04 5.81% 1Y
-2.70 80.96% 5Y
-3.63 85.11% 10Y
+0.24 58.95% 20Y
NYSE, Closing price Fri, Jun 13 2025
+0.04 6.68%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $61.40m
Enterprise Value $66.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 50.40
P/S ratio (TTM) P/S ratio 46.87
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 61.73%
Revenue (TTM) Revenue $1.31m
EBIT (operating result TTM) EBIT $-24.16m
Free Cash Flow (TTM) Free Cash Flow $-22.35m
Cash position $2.60m
EPS (TTM) EPS $-0.27
P/E forward negative
P/S forward 9.63
EV/Sales forward 10.36
Short interest 0.25%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a VolitionRX forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a VolitionRX forecast:

Buy
83%
Hold
17%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.31 1.31
62% 62%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
22% 22%
983%
- Research and Development Expense 11 11
38% 38%
863%
-23 -23
33% 33%
-1,746%
- Depreciation and Amortization 1.29 1.29
8% 8%
98%
EBIT (Operating Income) EBIT -24 -24
32% 32%
-1,844%
Net Profit -24 -24
31% 31%
-1,834%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
one day ago
Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit...
Neutral
PRNewsWire
9 days ago
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentat...
Neutral
PRNewsWire
26 days ago
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 85
Founded 1998
Website volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today